Introduction

Autoimmunity Reviews

Volumn 10, Issue 5, 2011, Pages 239-240

  Chighizola, Cecilia ^a   Shoenfeld, Yehuda ^b   Meroni, Pier Luigi ^c  

^a ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^b SHEBA MEDICAL CENTER   (Israel)

^c ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CONNECTIVE TISSUE GROWTH FACTOR; CYCLOPHOSPHAMIDE; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN;

ANTIBODY PRODUCTION; AUTOIMMUNITY; CELL PROLIFERATION; CLINICAL FEATURE; EDITORIAL; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNE DYSREGULATION; INTERSTITIAL LUNG DISEASE; MACROPHAGE; NONHUMAN; PATHOGENESIS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE; FIBROSIS; IMMUNITY; ORGANIZATION; PATHOLOGY; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

CONGRESSES AS TOPIC; ENDOTHELIUM, VASCULAR; FIBROSIS; HUMANS; IMMUNE SYSTEM PHENOMENA; SCLERODERMA, SYSTEMIC;

EID: 79953885257     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.02.005     Document Type: Editorial

References (14)

1. Chizzolini C, Brembilla NC, Montanari E, Truchetet ME. Fibrosis and immune dysregulation in systemic sclerosis. Autoimmun Rev, doi:10.1016/j.autrev.2010.09.016.
2. Grossman C, Dovrish Z, Shoenfeld Y, Amital H. Do infections facilitate the emergence of Systemic Sclerosis? Autoimmun Rev, doi:10.1016/j.autrev.2010.09.010.
3. Wei J, Bhattacharyya S, Tourtellotte WG, Varga J. Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy. Autoimmun Rev
4. Walker J.G., Fritzler M.J. Update on autoantibodies in systemic sclerosis. Curr Opin Rheumatol 2007, 19:580-591.
5. Mahler M., Fritzler M.J. PM1-Alpha ELISA: the assay of choice for the detection of anti-PM/Scl autoantibodies?. Autoimmun Rev 2009, 8:373-378.
6. Shoenfeld Y., Czömpöly T., Simon D., Czirják L., Németh P. Anti-topoisomerase I autoantibodies in systemic sclerosis. Autoimmun Rev 2009, 8:692-696.
7. Koenig M., Dieudé M., Senécal J.L. Predictive value of antinuclear autoantibodies: the lessons of the systemic sclerosis autoantibodies. Autoimmun Rev 2008, 7:588-593.
8. Dieudé P, Boileau C, Allanore Y. Immunogenetics of systemic sclerosis. Autoimmun Rev (this issue).
9. Godard D. The needs of patients with systemic sclerosis-what are the difficulties encountered? Autoimmun Rev (this issue).
10. Mosca M, Tani C, Talarico R, Bombardieri S. Undifferentiated connective tissue diseases (UCTD): simplified systemic autoimmune diseases. Autoimmun Rev (this issue).
11. Galluccio F, Matucci-Cerinic M. Two faces of the same coin: Raynaud phenomenon and digital ulcers in systemic sclerosis. Autoimmun Rev (this issue).
12. Nussinovitch U, Shoenfeld Y. Atherosclerosis and Macrovascular Involvement in Systemic Sclerosis: Myth or Reality. Autoimmun Rev (this issue).
13. Bussone G, Mouthon L. Interstitial lung disease in systemic sclerosis. Autoimmun Rev (this issue).
14. Ramos-Casals M., Fonollosa-Pla V., Brito-Zerón P., Sisó-Almirall A. Targeted therapy for systemic sclerosis: how close are we?. Nat Rev Rheumatol 2010, 6:269-278.